Emtriva researcher prepares to launch new biotech

One of the researchers involved in Emory University's record-setting $525 million licensing deal for the HIV drug Emtriva plans to use part of his cut to set up a new bioscience company in Atlanta. Raymond Schinazi says he plans to spend about $12 million to start RFS Pharma, which will concentrate on developing antiviral and anti-cancer drugs. Another biotech company started by Schinazi, Pharmasset, recently announced plans to move to Princeton, New Jersey.

- read this report from the Atlanta Business Chronicle for more

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.